Consumer Electronics company Symphony announced Q1FY25 results: Consolidated Revenue from Operations: Rs 531 crore in the quarter ended June 2024, a 76% increase from Rs 302 crore in the same quarter of 2023. Standalone Revenue from Operations: Rs 373 crore in the quarter ended June 2024, reflecting a 116% increase compared to Rs 172 crore in Q1FY24. Consolidated Gross Margin: 51.2% for Q1FY25, up by 150 basis points from 49.7% in Q1FY24. Standalone Gross Margin: 52.8% for Q1FY25, an increase of 130 basis points from 51.5% in Q1FY24. Consolidated EBITDA Margin (excluding other income and foreign exchange loss): 21.0% in Q1FY25, a substantial increase of 1,170 basis points from 9.3% in Q1FY24. Standalone EBITDA Margin (excluding other income and foreign exchange loss): 22.0% for Q1FY25, up by 1,780 basis points from 4.2% in Q1FY24. Consolidated Profit After Tax (PAT): Rs 88 crore in Q1FY25, marking a 270% increase from Rs 24 crore in Q1FY24. Standalone Profit After Tax (PAT): Rs 69 crore for Q1FY25, which is a 375% increase compared to Rs 14 crore in Q1FY24. Nrupesh Shah, Managing Director (Corporate Affairs), Symphony Limited has commented: “Performance Highlights for quarter ended on June 30, 2024: Strong Jun’24 standalone performance driven by: Scorching and crippling heatwave Strong penetration in semi-urban and rural markets D2C: A growth driver; 100% prepaid (No COD) Highest ever quarterly Revenue & PAT (Standalone and Consol.): Growth in domestic sales 117% YoY (Jun’23) & 58 % v/s historical best any quarter Improvement in EBITDA margin: Gross margin expansion Positive operating leverage Strong performance of IMPCO Mexico and GSK China IMPCO, Mexico: Robust YoY growth: Revenue 46%, EBITDA 36% & PAT 77% Highest ever quarterly Revenue, EBITDA, and PAT CT, Australia: Demand headwind persists Business transformation progressing as planned GSK, China: Strong positive top-line and bottom-line performance Result PDF